Oncternal Therapeutics Inc Shares Close the Day 11.6% Lower - Daily Wrap
The company saw its shares close the day 11.6% lower than yesterday, with trading volume higher than its 30 day average.
Apr 07, 2021 by Kwhen Finance Editors
Oncternal Therapeutics Inc shares closed today 11.6% lower than it did at the end of yesterday. The stock is currently up 68.6% year-to-date, up 195.0% over the past 12 months, and up 43.4% over the past five years. Today, the Dow Jones Industrial Average rose 0.8%, and the S&P 500 rose 0.7%.
Trading Activity
- Shares traded as high as $10.56 and as low as $7.81 this week.
- Shares closed 2e+1% below its 52-week high and 5e+2% above its 52-week low.
- Trading volume this week was 38.6% lower than the 10-day average and 13.7% lower than the 30-day average.
- Beta, a measure of the stock’s volatility relative to the overall market stands at 1.1.
Technical Indicators
- The Relative Strength Index (RSI) on the stock was between 30 and 70.
- MACD, a trend-following momentum indicator, indicates an upward trend.
- The stock closed below its Bollinger band, indicating it may be oversold.
- The stock closed at 5.9% lower than its 5-day moving average, 1.4% lower than its 20-day moving average, and 33.8% higher than its 90-day moving average.
Fundamentals & Catalysts
- Over the past 12 months the company generated $-15,279,000 in earnings before interest and taxes from $2 million in revenue. It currently holds $21 million in cash and $7 million in debt.
- Its forward price-to-earnings (P/E) ratio of -11.067797102143272 is higher than its current P/E ratio of -23.67, implying that analysts are expecting a decrease in earnings.
- The company's price/earnings-to-growth ratio (PEG Ratio), a widely used indicator of a stock's true value while also factoring in expected earnings growth, currently stands at -0.21. A fairly valued company should have a PEG ratio of 1.0. When a company's PEG exceeds 1.0, it's considered overvalued while a stock with a PEG of less than 1.0 is considered undervalued.
- The company's debt-to-equity ratio, which measures the extent to which it finances its operations through debt, currently stands at 1.50 which means it currently has $1.50 of debt for every $1 of equity. Generally speaking, a debt to equity ratio below 1.0 is seen as relatively safe, while ratios of 2.0 or higher would be considered risky. Some industries are known for having much higher debt to equity ratios than others.
- The company's price-to-book ratio, which measures the market's valuation of a company relative to its book value, currently stands at 17.26. This means that the stock is trading at a premium of 17 times relative to the company's book value which reflects the total value of a company's assets that shareholders of that company would receive if the company were to be liquidated.
- The company's price-to-sales ratio, which shows how much the market values every dollar of the company's sales, currently stands at 90.56.
- The company's enterprise value-to-revenue multiple, which is often used to determine a company's valuation in the case of a potential acquisition, currently stands at 83.56.
P/E
-23.67
EBITDA
$-15,279,000
P/Book
17.26
Mkt Cap
$407M
P/Sales
90.56
Revenue
$2M
EPS (TTM)
-0.85
PEG Ratio
-0.21
EV/Revenue
83.56
Total Cash
$21M
Debt/Equity
1.50
Forward P/E
-11.07
Current Debt
$7M
Gross Profit
$2M
Dividend Date
-
Earnings Date
2021-05-06
Profit Margin
-5.12
Revenue/Share
0.07
Total Revenue
$2M
Enterprise Val
$250M
Put/Call Ratio
0.27
Revenue/Employee
0.00
Market Comparative Performance
- The company's share price lags the S&P 500 Index today, beats it on a 1-year basis, and lags it on a 5-year basis
- The company's share price lags the Dow Jones Industrial Average today, beats it on a 1-year basis, and lags it on a 5-year basis
- The company share price lags the performance of its peers in the Health Care industry sector today, beats it on a 1-year basis, and lags it on a 5 year basis
| Name | DoD %Δ | YTD %Δ | 1 Yr % | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|
| Oncternal Therapeutics Inc | -11.6 | 68.6 | 195.0 | -24.2 | 436.9 |
| Dow Jones Industrial Average | 0.8 | 11.0 | 45.3 | -0.7 | 49.9 |
| S&P 500 Index | 0.7 | 10.4 | 50.3 | -0.8 | 52.9 |
| Health Care | 1.0 | 3.9 | 28.1 | -2.5 | 29.5 |
Peer Group Comparative Performance
- The company's stock price performance year-to-date beats the peer average by 41.2%
- The company's stock price performance over the past 12 months beats the peer average by 132.2%
| Name | MKT CAP (USD) | P/E | YTD %Δ | 1 Yr %Δ | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|---|
| Oncternal Therapeutics Inc | ONCT | -23.7 | 68.6 | 195.0 | -24.2 | 436.9 |
| Peer Avg | N/A | 0 | 48.5 | 84.0 | -27.3 | 188.2 |
| Ocular Therapeutix Inc | OCUL | 0 | -20.2 | 204.6 | -30.6 | 254.4 |
| OncoCyte Corp | OCX | 0 | 122.4 | 117.8 | -20.1 | 356.5 |
| Oragenics Inc. | OGEN | 0 | 92.0 | 13.5 | -58.4 | 141.7 |
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.
Was this content valuable for you?
Tags: